STUDYID,RDOMAIN,USUBJID,IDVAR,IDVARVAL,QNAM,QLABEL,QVAL,QORIG
NIDA-CTN-0002,AE,02_000549,AESEQ,1324,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1325,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1326,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1327,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1328,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1329,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1330,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1331,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1332,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1333,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1334,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1335,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1336,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1337,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1338,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1339,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1340,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_000549,AESEQ,1341,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_000852,AESEQ,796,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000852,AESEQ,797,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000852,AESEQ,798,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_000852,AESEQ,799,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002365,AESEQ,129,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002365,AESEQ,130,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002365,AESEQ,131,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002365,AESEQ,132,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002365,AESEQ,133,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1084,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1085,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1086,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1087,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1088,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1089,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1090,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1091,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1092,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1093,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1094,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1095,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1096,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1097,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1098,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1099,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1100,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1101,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1102,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_002504,AESEQ,1103,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,371,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,372,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,373,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,374,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,375,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,376,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,377,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,378,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,379,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,380,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,381,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,382,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,383,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,384,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,385,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,386,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,387,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,388,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,389,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_003272,AESEQ,390,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_003614,AESEQ,633,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_004450,AESEQ,40,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,139,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,140,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,141,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,142,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,143,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,144,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,AEDOB,DATE OF BIRTH (SAE PAGE),1960,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,AEHGT,HEIGHT (SAE PAGE),62,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,AESEX,SEX (SAE PAGE),FEMALE,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,AEWGT,WEIGHT (SAE PAGE),100,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,NO,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",SMOKES 4-5 CIGARETTES DAILY. TREATED FOR HYPETENSTION 6 MOS AGO FOR ONE MONTH.,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,145,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",--/--/01-ECG NORMAL; ONE PREMATURE ATRIAL CONTRACTION - NOT CLINICALLY SIGNIFICANT.,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,146,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,147,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_004483,AESEQ,148,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,956,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,957,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,958,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,959,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,960,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,961,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,962,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,963,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,964,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,965,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,966,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,967,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,968,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,969,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,970,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,971,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,972,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,973,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,974,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,975,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,976,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,977,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,978,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,979,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,980,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,981,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,982,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,983,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,984,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,985,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005069,AESEQ,986,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1261,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1262,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1263,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1264,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1265,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1266,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1267,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1268,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1269,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1270,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1271,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1272,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1273,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1274,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1275,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1276,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_005418,AESEQ,1277,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_006479,AESEQ,523,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_006479,AESEQ,524,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_006759,AESEQ,761,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_006759,AESEQ,762,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_006759,AESEQ,763,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_006759,AESEQ,764,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_006759,AESEQ,765,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_006759,AESEQ,766,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,933,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,934,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,935,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,936,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,937,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,938,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,939,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,940,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,941,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,942,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,943,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,944,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,945,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,946,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,947,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,948,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,949,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,950,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,951,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,952,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,953,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,954,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_007784,AESEQ,955,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1543,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1544,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1545,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1546,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1547,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1548,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1549,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1550,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1551,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1552,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1553,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1554,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1555,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1556,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1557,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1558,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1559,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1560,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1561,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1562,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1563,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1564,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008479,AESEQ,1565,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008499,AESEQ,254,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008499,AESEQ,255,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_008499,AESEQ,256,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008499,AESEQ,257,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008499,AESEQ,258,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008499,AESEQ,259,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008499,AESEQ,260,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008499,AESEQ,261,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008499,AESEQ,262,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008740,AESEQ,120,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008740,AESEQ,121,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008740,AESEQ,122,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008740,AESEQ,123,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008740,AESEQ,124,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_008740,AESEQ,125,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008740,AESEQ,126,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008740,AESEQ,127,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_008740,AESEQ,128,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1040,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1041,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1042,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1043,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1044,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1045,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1046,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1047,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1048,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1049,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1050,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1051,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1052,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1053,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1054,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1055,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1056,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1057,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1058,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1059,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1060,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1061,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1062,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009190,AESEQ,1063,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1743,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1744,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1745,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1746,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1747,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1748,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1749,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1750,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1751,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1752,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1753,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1754,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1755,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1756,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1757,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1758,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1759,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1760,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1761,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1762,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1763,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_009452,AESEQ,1764,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_011297,AESEQ,790,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_011297,AESEQ,791,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_011297,AESEQ,792,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_011297,AESEQ,793,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_011297,AESEQ,794,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_011297,AESEQ,795,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1074,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1075,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1076,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1077,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1078,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1079,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1080,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1081,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1082,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_011526,AESEQ,1083,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_011902,AESEQ,1,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_011902,AESEQ,2,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_012064,AESEQ,512,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_012064,AESEQ,513,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_012064,AESEQ,514,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_013283,AESEQ,767,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_013283,AESEQ,768,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_013283,AESEQ,769,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_013283,AESEQ,770,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_013283,AESEQ,771,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_013283,AESEQ,772,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,216,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,217,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,218,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,219,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,220,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,221,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,AEDOB,DATE OF BIRTH (SAE PAGE),1952,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,AEETHNIC,RACE/ETHNICITY (SAE PAGE),"WHITE, NOT OF HISPANIC ORIGIN",CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,AEHGT,HEIGHT (SAE PAGE),70,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,AESOUTOT,"OUTCOME - OTHER, SPECIFY",HOSPITAL DISCHARGE,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,AEWGT,WEIGHT (SAE PAGE),207,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IALOT,INV AGENT LOT NUMBER,620052,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IANAME,INV AGENT NAME,BUPRENORPHINE/N,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IAQUANT,INV AGENT QUANTITY,4,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,IAUNIT,INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1","HEPATITIS C HX WITH INTERFERON TX. DEPRESSTION TX IN PAST, NO H/O SI/SA; NICOTINE DEPENDEN",CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,RELHIST2,"RELEVANT HISTORY, PRE-EXIST COND, LINE 2","CE; RITALIN USE --/--/01, HX OF HYPERTENSION MULTIPLE NONMALIGNANT CHRONIC PAIN COMPLAINTS.",CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1","--/--/01 VITALS SITTING BP=144/92, P=88; STANDING BP = 130/90, P=100. --/--/01 ALT =20; AST=",CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,RELTEST2,"SAE - RELEVANT TESTS/LAB DATA, LINE 2",40; LDH=276 (H). --/--/01 HCV RNA QUAL = NOT DETECTED. --/--/01 CHEST XRAY NEGATIVE FOR PNEU,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,222,RELTEST3,"SAE - RELEVANT TESTS/LAB DATA, LINE 3",MOTHORAX OR OBVIOUS FRACTURE.,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,223,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,224,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,225,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_013437,AESEQ,226,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,492,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,AEDOB,DATE OF BIRTH (SAE PAGE),1950,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,AEHGT,HEIGHT (SAE PAGE),70,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,AEWGT,WEIGHT (SAE PAGE),217,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IALOT,INV AGENT LOT NUMBER,00620053,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IANAME,INV AGENT NAME,BUP/NX,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IAQUANT,INV AGENT QUANTITY,1,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IAUNIT,INV AGENT UNIT,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,IAUNTOTH,"INV AGENT UNIT - OTHER, SPECIFY",STUDY KIT,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1","PARTICIPANT STATES BEING HOSPITALIZED IN 1979, 1983 AND 1984 FOR PERITONITIS FOLLOWING",CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,RELHIST2,"RELEVANT HISTORY, PRE-EXIST COND, LINE 2","GASTRIC ULCER PERFORATION, DEPRESSION AND ANXIETY, AND FLU RESPECTIVELY.",CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",THE RELEVANT TEST/LABORATORY DATA ARE NOT CURRENTLY AVAILABLE TO THE SITE.,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,RELTEST2,"SAE - RELEVANT TESTS/LAB DATA, LINE 2",THEY WILL BE FORWARDED TO THE LEAD NODE AS SOON AS THEY BECOME AVAILABLE TO THE SITE UPON,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,RELTEST3,"SAE - RELEVANT TESTS/LAB DATA, LINE 3",RECEIPT OF PENDING MEDICAL RECORDS.,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SAENDC01,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SAEXDT01,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SAFREQ01,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SALOT01,SECONDARY INV AGENT LOT NUMBER,00620052,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,BUP/NX,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SAQUNT01,SECONDARY INV AGENT QUANTITY,1,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SAROUT01,SECONDARY INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SASTDC01,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SAUNIT01,SECONDARY INV AGENT UNIT,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_013991,AESEQ,493,SAUNTO01,"SECONDARY INV AGENT UNIT - OTHER, SPECIF",STUDY KIT,CRF
NIDA-CTN-0002,AE,02_015027,AESEQ,511,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_018880,AESEQ,496,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_018880,AESEQ,497,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_018880,AESEQ,498,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_018880,AESEQ,499,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,428,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,429,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,430,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,431,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,432,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,433,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,434,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,435,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,436,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,437,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,438,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,439,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,AEDOB,DATE OF BIRTH (SAE PAGE),1963,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,AEETHNIC,RACE/ETHNICITY (SAE PAGE),"WHITE, NOT OF HISPANIC ORIGIN",CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,AEHGT,HEIGHT (SAE PAGE),73,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,AEWGT,WEIGHT (SAE PAGE),239,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IALOT,INV AGENT LOT NUMBER,00620052,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IANAME,INV AGENT NAME,BUP/NAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IAQUANT,INV AGENT QUANTITY,2,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,IAUNIT,INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1","HX OF HYPERTENSION,HX OF BACK PAIN",CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",NO SIGNIFICANT TEST OR LAB ABNORMALITIES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAENDC01,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAENDC02,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAENDC03,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAENDC04,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAENDC05,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAENDC06,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAENDC07,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAEXDT01,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAEXDT02,SECONDARY INV AGENT EXP DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAEXDT03,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAEXDT04,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAEXDT05,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAEXDT06,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAEXDT07,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAFREQ01,SECONDARY INV AGENT FREQUENCY,FOUR TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAFREQ02,SECONDARY INV AGENT FREQUENCY,SINGLE DOSE,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAFREQ03,SECONDARY INV AGENT FREQUENCY,THREE TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAFREQ04,SECONDARY INV AGENT FREQUENCY,FOUR TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAFREQ05,SECONDARY INV AGENT FREQUENCY,FOUR TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAFREQ06,SECONDARY INV AGENT FREQUENCY,FOUR TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAFREQ07,SECONDARY INV AGENT FREQUENCY,FOUR TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAIVSD02,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAIVSD03,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAIVSD04,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAIVSD05,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAIVSD06,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAIVSD07,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAKNWN02,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAKNWN03,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAKNWN04,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAKNWN05,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAKNWN06,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAKNWN07,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SALOT01,SECONDARY INV AGENT LOT NUMBER,1089129,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SALOT02,SECONDARY INV AGENT LOT NUMBER,41900,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SALOT03,SECONDARY INV AGENT LOT NUMBER,HN12,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SALOT04,SECONDARY INV AGENT LOT NUMBER,9000826,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SALOT05,SECONDARY INV AGENT LOT NUMBER,1089129,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SALOT06,SECONDARY INV AGENT LOT NUMBER,9000826,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SALOT07,SECONDARY INV AGENT LOT NUMBER,9000826,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,ACETAMINOPHEN,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SANAME02,SECONDARY INVESTIGATIONAL AGENT NAME,TRAZADONE,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SANAME03,SECONDARY INVESTIGATIONAL AGENT NAME,TRIMETHOBENZAMI,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SANAME04,SECONDARY INVESTIGATIONAL AGENT NAME,OXAZEPAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SANAME05,SECONDARY INVESTIGATIONAL AGENT NAME,ACETAMINOPHEN,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SANAME06,SECONDARY INVESTIGATIONAL AGENT NAME,OXAZEPAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SANAME07,SECONDARY INVESTIGATIONAL AGENT NAME,OXAZEPAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAQUNT01,SECONDARY INV AGENT QUANTITY,325,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAQUNT02,SECONDARY INV AGENT QUANTITY,100,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAQUNT03,SECONDARY INV AGENT QUANTITY,250,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAQUNT04,SECONDARY INV AGENT QUANTITY,15,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAQUNT05,SECONDARY INV AGENT QUANTITY,325,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAQUNT06,SECONDARY INV AGENT QUANTITY,15,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAQUNT07,SECONDARY INV AGENT QUANTITY,15,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAROUT01,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAROUT02,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAROUT03,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAROUT04,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAROUT05,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAROUT06,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAROUT07,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASGDT02,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASGDT03,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASGDT04,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASGDT05,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASGDT06,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASGDT07,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASTDC01,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASTDC02,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASTDC03,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASTDC04,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASTDC05,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASTDC06,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SASTDC07,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAUNIT01,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAUNIT02,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAUNIT03,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAUNIT04,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAUNIT05,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAUNIT06,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,440,SAUNIT07,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,441,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,442,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,443,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,444,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_019588,AESEQ,445,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1697,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1698,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1699,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1700,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1701,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1702,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1703,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1704,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1705,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1706,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_019718,AESEQ,1707,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1631,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1632,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1633,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1634,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1635,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1636,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1637,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1638,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1639,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1640,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1641,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1642,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1643,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1644,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_020697,AESEQ,1645,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1422,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1423,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1424,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1425,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1426,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1427,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1428,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1429,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1430,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1431,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1432,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1433,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1434,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1435,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1436,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1437,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1438,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021152,AESEQ,1439,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021273,AESEQ,551,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021273,AESEQ,552,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021273,AESEQ,553,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021273,AESEQ,554,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021463,AESEQ,37,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021463,AESEQ,38,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021463,AESEQ,39,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1202,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1203,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1204,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1205,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1206,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1207,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1208,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1209,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1210,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1211,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1212,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1213,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1214,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1215,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1216,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1217,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1218,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_021976,AESEQ,1219,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023802,AESEQ,707,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023802,AESEQ,708,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023802,AESEQ,709,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,227,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,228,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,229,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,230,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,231,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,232,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,233,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,234,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,235,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,236,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,237,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,238,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,239,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,240,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,241,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,242,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,243,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,244,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,245,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,246,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,247,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_023926,AESEQ,248,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_024208,AESEQ,30,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_024208,AESEQ,31,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1577,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1578,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1579,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1580,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1581,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1582,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1583,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1584,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1585,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1586,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1587,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1588,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1589,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1590,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1591,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1592,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_025902,AESEQ,1593,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,277,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,278,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,279,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,AEDOB,DATE OF BIRTH (SAE PAGE),1981,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,AEETHNIC,RACE/ETHNICITY (SAE PAGE),"WHITE, NOT OF HISPANIC ORIGIN",CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,AEHGT,HEIGHT (SAE PAGE),67,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,AESOUTOT,"OUTCOME - OTHER, SPECIFY",TRANSFERRED RESIDENTIAL LEVEL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,AEWGT,WEIGHT (SAE PAGE),201,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IALOT,INV AGENT LOT NUMBER,00620052,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IANAME,INV AGENT NAME,BUPRENORPHINE/N,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IAQUANT,INV AGENT QUANTITY,2,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,IAUNIT,INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",H/O OBSESSIVE/COMPULSIVE DISORDER DX 6 YRS AGO.,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1","--/--/01 INTAKE URINE DRUG SCREEN POSITIVE FOR MORPHINE, NEGATIVE ALL ELSE.",CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SAENDC01,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SAEXDT01,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SAFREQ01,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SALOT01,SECONDARY INV AGENT LOT NUMBER,000389,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,DIPHENHYDRAMINE,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SAQUNT01,SECONDARY INV AGENT QUANTITY,100,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SAROUT01,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SASTDC01,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,280,SAUNIT01,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,281,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,282,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,283,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,AEDOB,DATE OF BIRTH (SAE PAGE),1981,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,AEETHNIC,RACE/ETHNICITY (SAE PAGE),"WHITE, NOT OF HISPANIC ORIGIN",CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,AEHGT,HEIGHT (SAE PAGE),67,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,AESOUTOT,"OUTCOME - OTHER, SPECIFY",DCD FROM HOSPITAL COMPLETED,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,AEWGT,WEIGHT (SAE PAGE),201,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IALOT,INV AGENT LOT NUMBER,00620052,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IANAME,INV AGENT NAME,BUPRENORPHINE/N,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IAQUANT,INV AGENT QUANTITY,2,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,IAUNIT,INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1","H/O OBSESIVE/COMPULSIDE DISORDER. H/O DEPRESSION, HEADACHES. NICOTINE AND ALCOHOL ABUSE.",CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,284,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",--/--/01 INTAKE URIN DRUG SCREEN. --/--/01 FINAL URINE DRUG SCREEN.,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,285,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,286,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026158,AESEQ,287,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAENDC01,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAENDC02,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAENDC03,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAEXDT01,SECONDARY INV AGENT EXP DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAEXDT02,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAEXDT03,SECONDARY INV AGENT EXP DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAFREQ01,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAFREQ02,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAFREQ03,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAIVSD02,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAIVSD03,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAKNWN02,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAKNWN03,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SALOT01,SECONDARY INV AGENT LOT NUMBER,41900,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SALOT02,SECONDARY INV AGENT LOT NUMBER,000389,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SALOT03,SECONDARY INV AGENT LOT NUMBER,41900,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,TRAZADONE/HYDRO,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SANAME02,SECONDARY INVESTIGATIONAL AGENT NAME,DIPHENHYDRAMINE,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SANAME03,SECONDARY INVESTIGATIONAL AGENT NAME,TRAZDONE/HYDROC,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAQUNT01,SECONDARY INV AGENT QUANTITY,150,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAQUNT02,SECONDARY INV AGENT QUANTITY,100,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAQUNT03,SECONDARY INV AGENT QUANTITY,150,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAROUT01,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAROUT02,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAROUT03,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SASGDT02,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SASGDT03,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SASTDC01,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SASTDC02,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SASTDC03,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAUNIT01,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAUNIT02,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_026158,USUBJID,020405081016,SAUNIT03,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1165,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1166,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1167,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1168,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1169,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1170,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1171,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1172,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1173,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1174,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1175,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1176,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1177,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1178,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1179,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1180,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1181,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_026834,AESEQ,1182,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_027208,AESEQ,619,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_027208,AESEQ,620,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,43,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,44,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,45,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,46,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,47,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,48,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,49,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,50,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,51,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,52,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,53,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,54,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,55,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_027910,AESEQ,56,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1440,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1441,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1442,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1443,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1444,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1445,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1446,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1447,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1448,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1449,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1450,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1451,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1452,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1453,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1454,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1455,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1456,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1457,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1458,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1459,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1460,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1461,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1462,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1463,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1464,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1465,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1466,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1467,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1468,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_028889,AESEQ,1469,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1285,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1286,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1287,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1288,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1289,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1290,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1291,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1292,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1293,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029080,AESEQ,1294,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1183,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1184,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1185,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1186,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1187,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1188,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1189,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1190,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1191,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1192,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1193,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1194,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1195,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1196,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1197,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1198,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1199,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1200,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029311,AESEQ,1201,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029448,AESEQ,677,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029611,AESEQ,704,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_029611,AESEQ,705,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1220,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1221,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1222,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1223,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1224,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1225,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1226,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1227,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1228,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1229,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1230,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1231,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1232,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1233,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1234,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1235,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1236,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1237,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1238,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1239,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,AEDOB,DATE OF BIRTH (SAE PAGE),1949,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,AEHGT,HEIGHT (SAE PAGE),66,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,AESEX,SEX (SAE PAGE),FEMALE,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,AEWGT,WEIGHT (SAE PAGE),120,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IAEXPDTC,INV AGENT EXPIRATION DATE,1911,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IAFREQ,INV AGENT FREQUENCY,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IAFRQOTH,"INV AGENT FREQUENCY - OTHER, SPECIFY",SEE COMMENTS,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IALOT,INV AGENT LOT NUMBER,01 0119,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IANAME,INV AGENT NAME,CLONIDINE KIT,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IAQUANT,INV AGENT QUANTITY,0,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IAROTH,"INV AGENT ROUTE - OTHER, SPECIFY",ORAL AND TRANSDERMAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IAROUTE,INV AGENT ROUTE,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,IAUNIT,INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",HX OF STOMACH ULCERS PANCREATITIS HX OF DIFFICULTY HEALING SORES HX OF ANEMIA PCN ALLERGY,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",08302001 CHLORIDE 109 WBC 10 TO 20,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,RELTEST2,"SAE - RELEVANT TESTS/LAB DATA, LINE 2",SP GRAV UA GREATER THAN 1 POINT 030,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,RELTEST3,"SAE - RELEVANT TESTS/LAB DATA, LINE 3",PROTEIN UA 30 MG PER DL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAENDC03,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAENDC04,SECONDARY INV AGENT END DATE,1911,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAENDC05,SECONDARY INV AGENT END DATE,1911,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAENDC06,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAENDC07,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAENDC08,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAENDC09,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAENDC10,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAENDC11,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAEXDT06,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAEXDT07,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAEXDT08,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAEXDT09,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAEXDT10,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAEXDT11,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ01,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ02,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ03,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ04,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ05,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ06,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ07,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ08,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ09,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ10,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ11,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ12,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ13,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ14,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAFREQ15,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD02,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD03,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD04,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD05,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD06,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD07,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD08,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD09,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD10,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD11,SECONDARY INV AGENT INVEST. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD12,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD13,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD14,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAIVSD15,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN02,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN03,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN04,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN05,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN06,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN07,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN08,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN09,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN10,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN11,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN12,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN13,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN14,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAKNWN15,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SALOT06,SECONDARY INV AGENT LOT NUMBER,KDO9,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SALOT07,SECONDARY INV AGENT LOT NUMBER,G02799,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SALOT08,SECONDARY INV AGENT LOT NUMBER,1089129,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SALOT09,SECONDARY INV AGENT LOT NUMBER,24I0GH00,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SALOT10,SECONDARY INV AGENT LOT NUMBER,15158C,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SALOT11,SECONDARY INV AGENT LOT NUMBER,0S914,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,PEROXIDE,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME02,SECONDARY INVESTIGATIONAL AGENT NAME,ALCOHOL RUB,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME03,SECONDARY INVESTIGATIONAL AGENT NAME,ANTIFUNGAL MEDI,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME04,SECONDARY INVESTIGATIONAL AGENT NAME,COCOBUTTER LOTI,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME05,SECONDARY INVESTIGATIONAL AGENT NAME,TOOTHPASTE,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME06,SECONDARY INVESTIGATIONAL AGENT NAME,TRIMETHOBENZAMI,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME07,SECONDARY INVESTIGATIONAL AGENT NAME,IBUPROFEN,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME08,SECONDARY INVESTIGATIONAL AGENT NAME,ACETAMINOPHEN,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME09,SECONDARY INVESTIGATIONAL AGENT NAME,LORAZEPAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME10,SECONDARY INVESTIGATIONAL AGENT NAME,LOPERAMIDE,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME11,SECONDARY INVESTIGATIONAL AGENT NAME,ZOLPIDEM TARTRA,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME12,SECONDARY INVESTIGATIONAL AGENT NAME,TYLENOL PM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME13,SECONDARY INVESTIGATIONAL AGENT NAME,IBUPROFEN,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME14,SECONDARY INVESTIGATIONAL AGENT NAME,ASPIRIN,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SANAME15,SECONDARY INVESTIGATIONAL AGENT NAME,IRON SUPPLEMENT,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT01,SECONDARY INV AGENT QUANTITY,999999,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT02,SECONDARY INV AGENT QUANTITY,999999,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT03,SECONDARY INV AGENT QUANTITY,999999,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT04,SECONDARY INV AGENT QUANTITY,999999,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT05,SECONDARY INV AGENT QUANTITY,999999,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT06,SECONDARY INV AGENT QUANTITY,250,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT07,SECONDARY INV AGENT QUANTITY,800,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT08,SECONDARY INV AGENT QUANTITY,325,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT09,SECONDARY INV AGENT QUANTITY,1,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT10,SECONDARY INV AGENT QUANTITY,2,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT11,SECONDARY INV AGENT QUANTITY,10,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT12,SECONDARY INV AGENT QUANTITY,525,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT13,SECONDARY INV AGENT QUANTITY,200,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT14,SECONDARY INV AGENT QUANTITY,325,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAQUNT15,SECONDARY INV AGENT QUANTITY,999999,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT01,SECONDARY INV AGENT ROUTE,TRANSDERMAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT02,SECONDARY INV AGENT ROUTE,TRANSDERMAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT03,SECONDARY INV AGENT ROUTE,VAGINAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT04,SECONDARY INV AGENT ROUTE,TRANSDERMAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT05,SECONDARY INV AGENT ROUTE,TRANSDERMAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT06,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT07,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT08,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT09,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT10,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT11,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT12,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT13,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT14,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAROUT15,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT02,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT03,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT04,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT05,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT06,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT07,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT08,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT09,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT10,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT11,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT12,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT13,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT14,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASGDT15,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASTDC03,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASTDC06,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASTDC07,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASTDC08,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASTDC09,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASTDC10,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SASTDC11,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT01,SECONDARY INV AGENT UNIT,UNKNOWN,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT02,SECONDARY INV AGENT UNIT,UNKNOWN,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT03,SECONDARY INV AGENT UNIT,SUPPOSITORY,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT04,SECONDARY INV AGENT UNIT,UNKNOWN,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT05,SECONDARY INV AGENT UNIT,UNKNOWN,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT06,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT07,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT08,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT09,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT10,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT11,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT12,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT13,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT14,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1240,SAUNIT15,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1241,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1242,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1243,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1244,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1245,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_030892,AESEQ,1246,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_031579,AESEQ,576,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031579,AESEQ,577,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031579,AESEQ,578,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031579,AESEQ,579,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031579,AESEQ,580,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031579,AESEQ,581,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031579,AESEQ,582,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031579,AESEQ,583,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,450,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,451,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,452,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,453,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,454,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,455,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,456,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,457,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,458,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,459,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,460,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,461,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,462,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_031720,AESEQ,463,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_032022,AESEQ,149,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_032022,AESEQ,150,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_032022,AESEQ,151,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_032208,AESEQ,621,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_032208,AESEQ,622,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_032208,AESEQ,623,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033272,AESEQ,11,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1310,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1311,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1312,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1313,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1314,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1315,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1316,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1317,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1318,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1319,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1320,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1321,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1322,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_033861,AESEQ,1323,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_034511,AESEQ,706,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,306,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,307,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,308,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,309,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,310,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,311,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,312,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,313,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,314,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,315,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,316,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,317,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,318,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,319,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,320,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,321,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,322,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,323,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,324,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,325,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,326,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,327,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,328,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,329,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,330,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,331,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,332,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,333,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,334,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,335,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,336,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,337,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,338,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,339,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,340,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,341,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,342,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_035542,AESEQ,343,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_035753,AESEQ,519,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_035753,AESEQ,520,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_035753,AESEQ,521,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_035753,AESEQ,522,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_036130,AESEQ,729,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036130,AESEQ,730,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036130,AESEQ,731,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,836,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,837,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,838,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,839,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,840,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,841,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,842,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,843,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,844,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,845,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,846,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,847,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,848,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,849,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,850,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,851,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,852,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,853,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,854,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,855,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,856,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,857,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,858,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036584,AESEQ,859,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036954,AESEQ,505,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_036954,AESEQ,506,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,169,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,170,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,171,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,172,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,173,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,174,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,175,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,176,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,177,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,178,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,179,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_036957,AESEQ,180,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_037966,AESEQ,738,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_037966,AESEQ,739,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_037966,AESEQ,740,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_037966,AESEQ,741,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_037966,AESEQ,742,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_037966,AESEQ,743,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_037966,AESEQ,744,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_037966,AESEQ,745,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_038350,AESEQ,710,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_038350,AESEQ,711,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_038350,AESEQ,712,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_038350,AESEQ,713,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_038350,AESEQ,714,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_038350,AESEQ,715,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_038844,AESEQ,509,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039051,AESEQ,1021,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039051,AESEQ,1022,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039051,AESEQ,1023,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039051,AESEQ,1024,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039051,AESEQ,1025,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039051,AESEQ,1026,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,152,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,153,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,154,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,155,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,156,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,157,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,158,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,159,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,160,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,161,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,162,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,163,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,164,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,165,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,166,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,167,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_039076,AESEQ,168,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,264,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,265,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,266,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,267,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,268,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,269,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,270,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,271,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,272,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,273,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,274,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,275,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_040804,AESEQ,276,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_041645,AESEQ,500,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_041645,AESEQ,501,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_041645,AESEQ,502,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1295,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1296,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1297,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1298,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1299,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1300,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1301,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1302,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1303,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1304,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1305,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1306,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1307,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1308,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_042358,AESEQ,1309,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,565,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,566,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,567,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,568,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,569,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,570,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,571,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,572,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,573,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,574,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043111,AESEQ,575,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043130,AESEQ,631,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043130,AESEQ,632,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1730,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1731,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1732,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1733,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1734,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1735,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1736,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1737,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1738,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1739,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1740,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1741,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_043156,AESEQ,1742,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_043183,AESEQ,263,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,12,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,13,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,14,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,AEDOB,DATE OF BIRTH (SAE PAGE),1961,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,AEETHNIC,RACE/ETHNICITY (SAE PAGE),"WHITE, NOT OF HISPANIC ORIGIN",CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,AEHGT,HEIGHT (SAE PAGE),70,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,AEWGT,WEIGHT (SAE PAGE),176,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,NO,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,1901,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",HISTORY OF ALCOHOL ABUSE,CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,15,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1","NONE, SAE BASED ON PARTICIPANTS SELF REPORT.",CRF
NIDA-CTN-0002,AE,02_044005,AESEQ,16,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1524,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1525,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1526,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1527,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1528,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1529,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1530,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1531,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1532,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1533,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1534,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1535,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1536,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1537,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1538,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1539,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1540,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1541,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044273,AESEQ,1542,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044380,AESEQ,134,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044380,AESEQ,135,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044380,AESEQ,136,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044380,AESEQ,137,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044380,AESEQ,138,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044708,AESEQ,503,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044708,AESEQ,504,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1064,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1065,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1066,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1067,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1068,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1069,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1070,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1071,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1072,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_044851,AESEQ,1073,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_044880,AESEQ,640,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,608,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,609,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,610,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,611,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,612,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,613,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,614,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,615,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,616,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,617,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045101,AESEQ,618,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045260,AESEQ,249,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045260,AESEQ,250,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_045260,AESEQ,251,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045260,AESEQ,252,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045260,AESEQ,253,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045563,AESEQ,81,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045563,AESEQ,82,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045563,AESEQ,83,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045563,AESEQ,84,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045563,AESEQ,85,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045563,AESEQ,86,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045563,AESEQ,87,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_045563,AESEQ,88,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_046717,AESEQ,727,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_046717,AESEQ,728,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_046737,AESEQ,720,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_046737,AESEQ,721,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_046737,AESEQ,722,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_046788,AESEQ,555,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_046788,AESEQ,556,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048107,AESEQ,510,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048454,AESEQ,365,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048454,AESEQ,366,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048454,AESEQ,367,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_048454,AESEQ,368,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048454,AESEQ,369,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048454,AESEQ,370,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,685,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,686,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,687,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,688,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,689,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,690,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,691,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,692,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,693,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,694,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,695,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,696,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,697,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048763,AESEQ,698,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,875,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,876,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,877,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,878,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,879,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,880,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,881,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,882,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,883,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,884,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,885,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,886,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,887,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,888,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,889,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,890,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,891,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048792,AESEQ,892,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048803,AESEQ,701,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048803,AESEQ,702,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_048803,AESEQ,703,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_049710,AESEQ,699,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_049710,AESEQ,700,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1027,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1028,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1029,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1030,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1031,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1032,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1033,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1034,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1035,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1036,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1037,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1038,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050165,AESEQ,1039,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,104,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,105,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,106,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,107,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,108,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,109,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,110,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,111,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,112,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,113,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,114,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,115,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,116,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,117,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,118,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050446,AESEQ,119,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1247,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1248,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1249,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1250,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1251,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1252,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1253,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1254,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1255,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1256,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1257,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1258,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1259,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_050489,AESEQ,1260,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_050771,AESEQ,630,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,67,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,68,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,69,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,70,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,71,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,72,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,73,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,74,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,75,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,AEDOB,DATE OF BIRTH (SAE PAGE),1952,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,AEHGT,HEIGHT (SAE PAGE),67,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,AEWGT,WEIGHT (SAE PAGE),162,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1","HISTORY OF SMOKING <1/2 PPD, HISTORY OF OCCASIONAL ALCOHOL USE - 1 BEER, 2-3 TIMES PER WEE",CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,RELHIST2,"RELEVANT HISTORY, PRE-EXIST COND, LINE 2",K.,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,76,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",N/A,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,AEDOB,DATE OF BIRTH (SAE PAGE),1952,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,AEHGT,HEIGHT (SAE PAGE),67,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,AEWGT,WEIGHT (SAE PAGE),162,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,NO,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",HX O/ HEROIN USE X 21 YEARS; LAST REPORTED USE -/-/01. HX OF ETOH USE X 26 YEARS - 1-2 BE,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,77,RELHIST2,"RELEVANT HISTORY, PRE-EXIST COND, LINE 2",ERS EVERY 2-3 DAYS. HX O/ TOBACCO USE X 26 YRS.,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,78,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,79,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_051268,AESEQ,80,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_052516,AESEQ,41,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1470,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1471,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1472,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1473,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1474,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1475,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1476,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1477,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1478,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1479,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1480,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1481,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1482,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1483,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1484,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1485,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1486,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1487,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1488,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1489,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,AEDOB,DATE OF BIRTH (SAE PAGE),1959,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,AEHGT,HEIGHT (SAE PAGE),60,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,AESEX,SEX (SAE PAGE),FEMALE,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,AEWGT,WEIGHT (SAE PAGE),136,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IAFREQ,INV AGENT FREQUENCY,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IAFRQOTH,"INV AGENT FREQUENCY - OTHER, SPECIFY",SEE P4 COMMENTS,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IALOT,INV AGENT LOT NUMBER,01 0119,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IANAME,INV AGENT NAME,CLONIDINE KIT,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IAQUANT,INV AGENT QUANTITY,0,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IAROTH,"INV AGENT ROUTE - OTHER, SPECIFY",ORAL AND TRANSDERMAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IAROUTE,INV AGENT ROUTE,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,IAUNIT,INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",ALLERGIES PCN LIBRIUM LEG EDEMA SEIZURE ON TIME 1979 DRUG RELATED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,RELHIST2,"RELEVANT HISTORY, PRE-EXIST COND, LINE 2",BRAIN ANEURYSM DRAINED IN SURGERY 1989 TUBAL LIGATION 1979,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,RELHIST3,"RELEVANT HISTORY, PRE-EXIST COND, LINE 3",METHADONE TX 1997 TO 1998 100 MG PER DAY OR LAAM SKIN POPPING 15 YRS,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",HEP C AB POS  EPITH CELLS UA SEVERAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,RELTEST2,"SAE - RELEVANT TESTS/LAB DATA, LINE 2",TRIGLYCERIDE 129 HIGH   SGOT 11 LOW,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,RELTEST3,"SAE - RELEVANT TESTS/LAB DATA, LINE 3",SP GRAV UA GREATER THAN 1 POINT 030 HIGH  RBC 3 POINT 9 LOW,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAENDC01,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAENDC02,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAENDC03,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAENDC04,SECONDARY INV AGENT END DATE,1911,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAENDC05,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAENDC06,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAEXDT01,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAEXDT03,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAFREQ01,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAFREQ02,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAFREQ03,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAFREQ04,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAFREQ05,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAFREQ06,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAIVSD02,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAIVSD03,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAIVSD04,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAIVSD05,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAIVSD06,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAKNWN02,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAKNWN03,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAKNWN04,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAKNWN05,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAKNWN06,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SALOT01,SECONDARY INV AGENT LOT NUMBER,05914,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SALOT02,SECONDARY INV AGENT LOT NUMBER,K009,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SALOT03,SECONDARY INV AGENT LOT NUMBER,G02799,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,ZOLPIDEM TARTRA,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SANAME02,SECONDARY INVESTIGATIONAL AGENT NAME,TRIMETHOBENZAMI,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SANAME03,SECONDARY INVESTIGATIONAL AGENT NAME,IBUPROFEN,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SANAME04,SECONDARY INVESTIGATIONAL AGENT NAME,GINSENG,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SANAME05,SECONDARY INVESTIGATIONAL AGENT NAME,MULTIVITAMEN,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SANAME06,SECONDARY INVESTIGATIONAL AGENT NAME,ACETAMINOPHEN,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAQUNT01,SECONDARY INV AGENT QUANTITY,10,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAQUNT02,SECONDARY INV AGENT QUANTITY,250,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAQUNT03,SECONDARY INV AGENT QUANTITY,800,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAQUNT04,SECONDARY INV AGENT QUANTITY,999999,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAQUNT05,SECONDARY INV AGENT QUANTITY,999999,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAQUNT06,SECONDARY INV AGENT QUANTITY,500,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAROUT01,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAROUT02,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAROUT03,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAROUT04,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAROUT05,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAROUT06,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASGDT02,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASGDT03,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASGDT04,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASGDT05,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASGDT06,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASTDC01,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASTDC02,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASTDC03,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASTDC04,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SASTDC06,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAUNIT01,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAUNIT02,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAUNIT03,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAUNIT04,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAUNIT05,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1490,SAUNIT06,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1491,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_053044,AESEQ,1492,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_054547,AESEQ,516,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_055867,AESEQ,42,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,288,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,289,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,290,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,291,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,292,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,293,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,294,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,295,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,296,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,297,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,298,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,299,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,300,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,301,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,302,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,303,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,304,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_055918,AESEQ,305,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,586,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,587,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,588,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,589,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,590,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,591,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,592,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,593,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,594,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,595,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,596,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,597,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,598,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,599,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_055979,AESEQ,600,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_056168,AESEQ,641,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_056191,AESEQ,562,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_056191,AESEQ,563,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_056191,AESEQ,564,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1359,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1360,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1361,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1362,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1363,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1364,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1365,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1366,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1367,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1368,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1369,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057805,AESEQ,1370,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057815,AESEQ,773,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_057815,AESEQ,774,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057815,AESEQ,775,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_057815,AESEQ,776,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057815,AESEQ,777,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_057815,AESEQ,778,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,893,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,894,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,895,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,896,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,897,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,898,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,899,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,900,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,901,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,902,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,903,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,904,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,905,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058028,AESEQ,906,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1610,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1611,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1612,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1613,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1614,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1615,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1616,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1617,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1618,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1619,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1620,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1621,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1622,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1623,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1624,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1625,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1626,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1627,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1628,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1629,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058079,AESEQ,1630,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,213,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,214,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,AEDOB,DATE OF BIRTH (SAE PAGE),1966,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,AEETHNIC,RACE/ETHNICITY (SAE PAGE),"WHITE, NOT OF HISPANIC ORIGIN",CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,AEHGT,HEIGHT (SAE PAGE),70,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,AESEX,SEX (SAE PAGE),FEMALE,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,AESOUTOT,"OUTCOME - OTHER, SPECIFY",HOSPITAL DISCHARGE,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,AEWGT,WEIGHT (SAE PAGE),261,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IALOT,INV AGENT LOT NUMBER,00620053,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IANAME,INV AGENT NAME,BUPRENORPHINE/N,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IAQUANT,INV AGENT QUANTITY,8,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,IAUNIT,INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1","BIOPOLAR DISORDER TXED FOR LAST 5 YEARS WITH DEPAKOTE; BULIMIA NERVOSA,COCAINE DEPENDENCE;",CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,RELHIST2,"RELEVANT HISTORY, PRE-EXIST COND, LINE 2","ALCOHOL DEPENDENCE IN REMISSION. CHRONIC PAIN UPPER BACK, MIDLINE,PRESENT SINCE LIPOMA EX",CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,RELHIST3,"RELEVANT HISTORY, PRE-EXIST COND, LINE 3",CISION 2YRS AGO POST OP STAPH INFECTION,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",--/--/01 URINE DRUG PANEL: COCAINE POSTITIVE NEG FOR ALL OTHER COMMON SUBSTANCES INCLUDING,CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,RELTEST2,"SAE - RELEVANT TESTS/LAB DATA, LINE 2","OPIATES. --/--/00 VALPORIC ACID 44 UG/ML:LOW, OUT OF THERAPUTIC RANGE. HOWEVER APPROPRIATE",CRF
NIDA-CTN-0002,AE,02_058212,AESEQ,215,RELTEST3,"SAE - RELEVANT TESTS/LAB DATA, LINE 3",FOR MANAGEMENT OF BIPOLAR DISORDER.,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,800,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,801,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,802,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,803,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,804,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,805,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,806,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,807,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,808,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,809,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,810,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,811,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,812,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,813,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,814,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058257,AESEQ,815,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058920,AESEQ,584,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_058920,AESEQ,585,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1646,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1647,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1648,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1649,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1650,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1651,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1652,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1653,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1654,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1655,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1656,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1657,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1658,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1659,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1660,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1661,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1662,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1663,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1664,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1665,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1666,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1667,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1668,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1669,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1670,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1671,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1672,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1673,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1674,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059257,AESEQ,1675,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_059903,AESEQ,26,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059903,AESEQ,27,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059903,AESEQ,28,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_059903,AESEQ,29,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,987,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,988,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,989,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,990,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,991,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,992,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,993,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,994,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,995,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,996,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,997,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_060475,AESEQ,998,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,57,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,58,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,59,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,60,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,61,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,62,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,63,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,64,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,65,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061003,AESEQ,66,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1493,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1494,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1495,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1496,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1497,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1498,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1499,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1500,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1501,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1502,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1503,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1504,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1505,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1506,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1507,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1508,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1509,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1510,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1511,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1512,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1513,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1514,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1515,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1516,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1517,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1518,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1519,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1520,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1521,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1522,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061173,AESEQ,1523,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1104,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1105,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1106,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1107,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1108,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1109,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1110,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1111,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1112,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1113,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1114,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1115,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1116,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1117,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1118,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1119,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1120,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1121,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1122,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1123,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1124,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1125,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1126,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1127,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1128,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1129,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_061221,AESEQ,1130,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,89,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,90,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,91,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,92,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,93,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,94,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,95,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,96,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,97,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,98,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,99,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,100,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,101,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,102,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_062244,AESEQ,103,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,860,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,861,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,862,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,863,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,864,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,865,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,866,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,867,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,868,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,869,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,870,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,871,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,872,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,873,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063128,AESEQ,874,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063158,AESEQ,716,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063158,AESEQ,717,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063158,AESEQ,718,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063158,AESEQ,719,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_063734,AESEQ,779,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,816,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,817,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,818,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,819,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,820,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,821,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,822,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,823,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,824,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,825,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,826,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,827,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,828,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,829,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,830,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,831,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,832,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,833,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,834,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065163,AESEQ,835,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_065400,AESEQ,746,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065400,AESEQ,747,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_065400,AESEQ,748,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065400,AESEQ,749,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065400,AESEQ,750,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065400,AESEQ,751,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065406,AESEQ,525,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065406,AESEQ,526,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065406,AESEQ,527,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065406,AESEQ,528,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065406,AESEQ,529,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_065406,AESEQ,530,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065406,AESEQ,531,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_065406,AESEQ,532,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_066131,AESEQ,601,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_066131,AESEQ,602,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_066131,AESEQ,603,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_066131,AESEQ,604,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_066131,AESEQ,605,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_066131,AESEQ,606,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_066131,AESEQ,607,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1342,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1343,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1344,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1345,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1346,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1347,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1348,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1349,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1350,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1351,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1352,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1353,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1354,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1355,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1356,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1357,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_067891,AESEQ,1358,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,999,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1000,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1001,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1002,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1003,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1004,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1005,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1006,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1007,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1008,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1009,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1010,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1011,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1012,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1013,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1014,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1015,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1016,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1017,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1018,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1019,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_067982,AESEQ,1020,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,482,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,483,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,484,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,485,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,486,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,487,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,488,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,489,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,490,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_068937,AESEQ,491,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_069875,AESEQ,533,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_069875,AESEQ,534,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1594,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1595,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1596,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1597,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1598,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1599,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1600,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1601,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1602,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1603,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1604,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1605,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1606,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1607,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1608,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_070154,AESEQ,1609,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_071868,AESEQ,557,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_071868,AESEQ,558,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_071868,AESEQ,559,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_071868,AESEQ,560,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_071868,AESEQ,561,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,756,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,AEDOB,DATE OF BIRTH (SAE PAGE),1967,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,AEHGT,HEIGHT (SAE PAGE),67,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,AEWGT,WEIGHT (SAE PAGE),204,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,IALOT,INV AGENT LOT NUMBER,00620052,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,IANAME,INV AGENT NAME,BUPRENORPHINZ,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,IAQUANT,INV AGENT QUANTITY,16,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,IAUNIT,INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",PAST HX ACUTE HEPATITIS TYPE UNKNOWN,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,RELHIST2,"RELEVANT HISTORY, PRE-EXIST COND, LINE 2",SELF REPORTED MILD DEPRESSION NO PRIOR TX,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",AAST 122 ALT 132 AT SCREENING - - 2001 GGTP 79 - - 2001,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,757,RELTEST2,"SAE - RELEVANT TESTS/LAB DATA, LINE 2",HEP C AB - - 2001,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,758,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,759,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_071895,AESEQ,760,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_072701,AESEQ,723,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_072701,AESEQ,724,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_072701,AESEQ,725,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_072701,AESEQ,726,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074166,AESEQ,634,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074166,AESEQ,635,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_074166,AESEQ,636,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074166,AESEQ,637,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_074166,AESEQ,638,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074166,AESEQ,639,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1150,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1151,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1152,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1153,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1154,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1155,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1156,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1157,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1158,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1159,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1160,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1161,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1162,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1163,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_074376,AESEQ,1164,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1566,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1567,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1568,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1569,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1570,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1571,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1572,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1573,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1574,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1575,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_074773,AESEQ,1576,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_075238,AESEQ,515,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_076025,AESEQ,17,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_076025,AESEQ,18,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_076025,AESEQ,19,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_076025,AESEQ,20,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_076025,AESEQ,21,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_076025,AESEQ,22,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_076025,AESEQ,23,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_076025,AESEQ,24,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_076025,AESEQ,25,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_077812,AESEQ,446,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_077812,AESEQ,447,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_077812,AESEQ,448,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_077812,AESEQ,449,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_078138,AESEQ,3,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_078138,AESEQ,4,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_078138,AESEQ,5,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_078138,AESEQ,6,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_078138,AESEQ,7,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_078658,AESEQ,785,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_078658,AESEQ,786,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_078658,AESEQ,787,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_078658,AESEQ,788,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_078658,AESEQ,789,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1131,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1132,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1133,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1134,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1135,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1136,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1137,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1138,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1139,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1140,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1141,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1142,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1143,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1144,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1145,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1146,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1147,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1148,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080478,AESEQ,1149,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,464,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,465,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,466,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,467,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,468,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,469,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,470,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,471,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,472,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,473,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,474,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,475,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,476,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,477,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,478,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,479,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,AEDOB,DATE OF BIRTH (SAE PAGE),1973,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,AEETHNIC,RACE/ETHNICITY (SAE PAGE),"WHITE, NOT OF HISPANIC ORIGIN",CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,AEHGT,HEIGHT (SAE PAGE),72,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,AEWGT,WEIGHT (SAE PAGE),148,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IALOT,INV AGENT LOT NUMBER,00620052,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IANAME,INV AGENT NAME,BUP/NAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IAQUANT,INV AGENT QUANTITY,2,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,IAUNIT,INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1","METAL ALLERGY,NECK PAIN,HEADACHE,DEPRESSION,SUICIDE ATT,SEIZURE.",CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",NONE RELEVANT TO THIS ADMISSION,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAENDC01,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAENDC02,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAENDC03,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAENDC04,SECONDARY INV AGENT END DATE,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAEXDT01,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAEXDT02,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAEXDT03,SECONDARY INV AGENT EXP DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAEXDT04,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAFREQ02,SECONDARY INV AGENT FREQUENCY,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAFREQ03,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAFREQ04,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAFRQO01,"SECONDARY INV AGENT FREQ - OTHER, SPECIF",2T Q 4-6H PRN,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAFRQO02,"SECONDARY INV AGENT FREQ - OTHER, SPECIF",2T Q 4-6H PRN,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAIVSD02,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAIVSD03,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAIVSD04,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAKNWN02,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAKNWN03,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAKNWN04,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SALOT01,SECONDARY INV AGENT LOT NUMBER,1089129,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SALOT02,SECONDARY INV AGENT LOT NUMBER,1089129,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SALOT03,SECONDARY INV AGENT LOT NUMBER,41900,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SALOT04,SECONDARY INV AGENT LOT NUMBER,000389,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,ACETAMINOPHEN,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SANAME02,SECONDARY INVESTIGATIONAL AGENT NAME,ACETAMINAPHIN,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SANAME03,SECONDARY INVESTIGATIONAL AGENT NAME,TRAZODONE,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SANAME04,SECONDARY INVESTIGATIONAL AGENT NAME,DIPHENHYDRAMINE,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAQUNT01,SECONDARY INV AGENT QUANTITY,325,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAQUNT02,SECONDARY INV AGENT QUANTITY,325,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAQUNT03,SECONDARY INV AGENT QUANTITY,100,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAQUNT04,SECONDARY INV AGENT QUANTITY,50,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAROUT01,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAROUT02,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAROUT03,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAROUT04,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SASGDT02,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SASGDT03,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SASGDT04,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SASTDC01,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SASTDC02,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SASTDC03,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SASTDC04,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAUNIT01,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAUNIT02,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAUNIT03,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,480,SAUNIT04,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_080480,AESEQ,481,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_080936,AESEQ,494,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_080936,AESEQ,495,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1676,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1677,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1678,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1679,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1680,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1681,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1682,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1683,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1684,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1685,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1686,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1687,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1688,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1689,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1690,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1691,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1692,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1693,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1694,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1695,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081016,AESEQ,1696,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_081045,AESEQ,624,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081045,AESEQ,625,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081045,AESEQ,626,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081045,AESEQ,627,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081045,AESEQ,628,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081045,AESEQ,629,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,344,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,345,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,346,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,347,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,348,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,349,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,350,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,351,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,352,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,353,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,354,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,355,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,356,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,357,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,358,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,359,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,360,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,AEDOB,DATE OF BIRTH (SAE PAGE),1952,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,AEETHNIC,RACE/ETHNICITY (SAE PAGE),"WHITE, NOT OF HISPANIC ORIGIN",CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,AEHGT,HEIGHT (SAE PAGE),73,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,AEWGT,WEIGHT (SAE PAGE),176,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IAFREQ,INV AGENT FREQUENCY,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IAFRQOTH,"INV AGENT FREQUENCY - OTHER, SPECIFY",CHANGE PATCH EVERY 7 DAYS,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IALOT,INV AGENT LOT NUMBER,9907766,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IANAME,INV AGENT NAME,CLONIDINE TTS 1,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IAQUANT,INV AGENT QUANTITY,4,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IAROUTE,INV AGENT ROUTE,TRANSDERMAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,IAUNIT,INV AGENT UNIT,PATCH,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1","PREVIOUS DX OF HYPERTENSION,NO CURRENT TX,OCCASSIONAL BACK PAIN-SOMETIMES EXACERBATED.",CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",ALL LABS NORMAL(INCLUDING LIVER ENZYMES)EXCEPT HEP C.,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC01,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC02,SECONDARY INV AGENT END DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC03,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC04,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC05,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC06,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC07,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC08,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC09,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC10,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC11,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAENDC12,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT01,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT02,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT03,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT04,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT05,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT06,SECONDARY INV AGENT EXP DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT07,SECONDARY INV AGENT EXP DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT08,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT09,SECONDARY INV AGENT EXP DATE,2003,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT10,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT11,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAEXDT12,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ01,SECONDARY INV AGENT FREQUENCY,THREE TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ02,SECONDARY INV AGENT FREQUENCY,THREE TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ03,SECONDARY INV AGENT FREQUENCY,FOUR TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ04,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ05,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ06,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ07,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ08,SECONDARY INV AGENT FREQUENCY,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ09,SECONDARY INV AGENT FREQUENCY,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ10,SECONDARY INV AGENT FREQUENCY,AS NEEDED,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ11,SECONDARY INV AGENT FREQUENCY,FOUR TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFREQ12,SECONDARY INV AGENT FREQUENCY,THREE TIMES A DAY,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFRQO08,"SECONDARY INV AGENT FREQ - OTHER, SPECIF",2CAPS INITIAL-1 CAP/EACH LOOSE,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAFRQO09,"SECONDARY INV AGENT FREQ - OTHER, SPECIF",2CAPS INITIAL-1 CAP/EACH LOOSE,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD02,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD03,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD04,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD05,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD06,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD07,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD08,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD09,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD10,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD11,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAIVSD12,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN02,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN03,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN04,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN05,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN06,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN07,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN08,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN09,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN10,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN11,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAKNWN12,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT01,SECONDARY INV AGENT LOT NUMBER,G02799,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT02,SECONDARY INV AGENT LOT NUMBER,G02799,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT03,SECONDARY INV AGENT LOT NUMBER,9000826,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT04,SECONDARY INV AGENT LOT NUMBER,HN12,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT05,SECONDARY INV AGENT LOT NUMBER,HN12,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT06,SECONDARY INV AGENT LOT NUMBER,41900,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT07,SECONDARY INV AGENT LOT NUMBER,41900,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT08,SECONDARY INV AGENT LOT NUMBER,117330,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT09,SECONDARY INV AGENT LOT NUMBER,117330,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT10,SECONDARY INV AGENT LOT NUMBER,HN12,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT11,SECONDARY INV AGENT LOT NUMBER,9000826,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SALOT12,SECONDARY INV AGENT LOT NUMBER,G02799,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,IBUPROFEN,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME02,SECONDARY INVESTIGATIONAL AGENT NAME,IBUPROPHINE,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME03,SECONDARY INVESTIGATIONAL AGENT NAME,OXAZEPAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME04,SECONDARY INVESTIGATIONAL AGENT NAME,TRIMETHOBENZAMI,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME05,SECONDARY INVESTIGATIONAL AGENT NAME,TRIMETHOBENZAMI,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME06,SECONDARY INVESTIGATIONAL AGENT NAME,TRAZADONE,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME07,SECONDARY INVESTIGATIONAL AGENT NAME,TRAZADONE,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME08,SECONDARY INVESTIGATIONAL AGENT NAME,LOPERAMIDE,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME09,SECONDARY INVESTIGATIONAL AGENT NAME,LOPERAMIDE,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME10,SECONDARY INVESTIGATIONAL AGENT NAME,TRIMETHOBENZAMI,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME11,SECONDARY INVESTIGATIONAL AGENT NAME,OXAZEPAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SANAME12,SECONDARY INVESTIGATIONAL AGENT NAME,IBUPROPHINE,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT01,SECONDARY INV AGENT QUANTITY,800,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT02,SECONDARY INV AGENT QUANTITY,800,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT03,SECONDARY INV AGENT QUANTITY,15,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT04,SECONDARY INV AGENT QUANTITY,250,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT05,SECONDARY INV AGENT QUANTITY,250,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT06,SECONDARY INV AGENT QUANTITY,50,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT07,SECONDARY INV AGENT QUANTITY,50,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT08,SECONDARY INV AGENT QUANTITY,2,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT09,SECONDARY INV AGENT QUANTITY,2,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT10,SECONDARY INV AGENT QUANTITY,250,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT11,SECONDARY INV AGENT QUANTITY,15,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAQUNT12,SECONDARY INV AGENT QUANTITY,800,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT01,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT02,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT03,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT04,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT05,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT06,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT07,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT08,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT09,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT10,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT11,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAROUT12,SECONDARY INV AGENT ROUTE,ORAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT02,SECONDARY INV AGENT PHYSIC. SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT03,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT04,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT05,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT06,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT07,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT08,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT09,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT10,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT11,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASGDT12,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC01,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC02,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC03,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC04,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC05,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC06,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC07,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC08,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC09,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC10,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC11,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SASTDC12,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT01,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT02,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT03,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT04,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT05,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT06,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT07,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT08,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT09,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT10,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT11,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,361,SAUNIT12,SECONDARY INV AGENT UNIT,MILLIGRAM,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,362,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,363,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081535,AESEQ,364,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_081773,AESEQ,8,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081773,AESEQ,9,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_081773,AESEQ,10,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083094,AESEQ,208,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083094,AESEQ,209,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_083094,AESEQ,210,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083094,AESEQ,211,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083094,AESEQ,212,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,33,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,AEDOB,DATE OF BIRTH (SAE PAGE),1949,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,AEHGT,HEIGHT (SAE PAGE),71,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,AEWGT,WEIGHT (SAE PAGE),169,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,NO,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2001,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,34,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",PT IS HIV POSITIVE. HE SMOKES ONE PACK OF CIGARRETTES PER DAY.,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,35,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_083268,AESEQ,36,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,391,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,392,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,393,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,394,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,395,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,396,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,397,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,398,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,399,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,400,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,401,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,402,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,403,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,404,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,405,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,406,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,407,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,408,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,409,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,410,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,411,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,412,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,413,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_083701,AESEQ,414,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,415,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,416,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,417,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,418,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,419,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,420,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,421,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,422,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,423,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,424,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,425,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,426,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_084318,AESEQ,427,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,507,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,AEDOB,DATE OF BIRTH (SAE PAGE),1959,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,AEHGT,HEIGHT (SAE PAGE),66,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,AEWGT,WEIGHT (SAE PAGE),165,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IALOT,INV AGENT LOT NUMBER,00620053,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IANAME,INV AGENT NAME,BUP/NX,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IAQUANT,INV AGENT QUANTITY,1,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IAUNIT,INV AGENT UNIT,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,IAUNTOTH,"INV AGENT UNIT - OTHER, SPECIFY",STUDY KIT,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",HISTORY OF CHRONIC BRONCHITIS ON PROVENTIL INHALER. CHRONIC NICOTINE USE (SMOKING,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1",RELEVANT TESTS/LABORATORY DATA ARE NOT CURRENTLY AVAILABLETO THE SITE. WHEN RECEIPT OF,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,RELTEST2,"SAE - RELEVANT TESTS/LAB DATA, LINE 2","PENDING MEDICAL RECORDS, SUCH DATA WILL BE FORWARDED TO THE LEAD NODE ASAP.",CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SAENDC01,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SAEXDT01,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SAFREQ01,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SALOT01,SECONDARY INV AGENT LOT NUMBER,00620052,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,BUP/NX,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SAQUNT01,SECONDARY INV AGENT QUANTITY,1,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SAROUT01,SECONDARY INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SASTDC01,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SAUNIT01,SECONDARY INV AGENT UNIT,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_086880,AESEQ,508,SAUNTO01,"SECONDARY INV AGENT UNIT - OTHER, SPECIF",STUDY KIT,CRF
NIDA-CTN-0002,AE,02_087712,AESEQ,32,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_088486,AESEQ,1278,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_088486,AESEQ,1279,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_088486,AESEQ,1280,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_088486,AESEQ,1281,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_088486,AESEQ,1282,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_088486,AESEQ,1283,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_088486,AESEQ,1284,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1371,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1372,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1373,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1374,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1375,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1376,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1377,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1378,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1379,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1380,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1381,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1382,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1383,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1384,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1385,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1386,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1387,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1388,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1389,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1390,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1391,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1392,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1393,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1394,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_089049,AESEQ,1395,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_090309,AESEQ,780,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_090309,AESEQ,781,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_090309,AESEQ,782,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_090309,AESEQ,783,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_090309,AESEQ,784,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,907,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,908,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,909,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,910,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,911,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,912,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,913,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,914,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,915,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,916,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,917,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,918,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,919,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,920,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,921,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,922,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,923,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,924,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,925,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,926,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,927,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,928,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,929,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,930,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,931,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091271,AESEQ,932,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091614,AESEQ,678,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091614,AESEQ,679,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091614,AESEQ,680,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091614,AESEQ,681,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091614,AESEQ,682,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091614,AESEQ,683,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091614,AESEQ,684,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1396,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1397,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1398,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1399,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1400,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1401,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1402,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1403,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1404,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1405,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1406,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1407,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1408,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1409,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1410,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1411,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1412,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1413,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1414,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1415,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1416,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1417,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1418,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1419,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1420,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091644,AESEQ,1421,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,664,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,665,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,666,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,667,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,668,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,669,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,670,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,671,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,672,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,673,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_091708,AESEQ,674,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1708,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1709,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1710,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1711,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1712,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1713,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1714,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1715,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1716,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1717,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1718,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1719,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1720,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1721,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1722,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1723,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1724,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1725,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1726,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1727,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1728,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_092341,AESEQ,1729,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_093160,AESEQ,642,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_093160,AESEQ,643,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_093160,AESEQ,644,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_093160,AESEQ,645,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,646,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,647,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,648,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,649,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,650,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,651,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,652,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,653,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,654,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_093746,AESEQ,655,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,517,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,AEDOB,DATE OF BIRTH (SAE PAGE),1954,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,AEHGT,HEIGHT (SAE PAGE),73,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,AEHGTU,HEIGHT UNITS (SAE PAGE),INCHES,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,AERANDDT,RANDOMIZATION DATE (SAE PAGE),2001,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,AESEX,SEX (SAE PAGE),MALE,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,AEWGT,WEIGHT (SAE PAGE),224,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,AEWGTU,WEIGHT UNITS (SAE PAGE),POUNDS,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,DRSIGDT,INV AGENT DATE PHYSICIAN SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IAENDTC,INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IAEXPDTC,INV AGENT EXPIRATION DATE,2002,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IAFREQ,INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IAKNOWN,IS INVEST. AGENT INFORMATION KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IALOT,INV AGENT LOT NUMBER,00620053,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IANAME,INV AGENT NAME,BUP/NX,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IAQUANT,INV AGENT QUANTITY,1,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IAROUTE,INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IASTDTC,INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IAUNIT,INV AGENT UNIT,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,IAUNTOTH,"INV AGENT UNIT - OTHER, SPECIFY",STUDY KIT,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,INVSIGDT,INV AGENT DATE INVESTIGATOR SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,RELHIST1,"RELEVANT HISTORY, PRE-EXIST COND, LINE 1",PARTICIPANT STATES BEING HOSPITALIZED FOR 3 DAYS IN 1977 FOR A FEVER OF UNKNOWN ORIGIN,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,RELHIST2,"RELEVANT HISTORY, PRE-EXIST COND, LINE 2",WHILE IN THE MILITARY AND IN 1999  FOR 10 DAYS FOR AN EYE INJURY AT HIS EMPLOYMENT.  PART-,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,RELHIST3,"RELEVANT HISTORY, PRE-EXIST COND, LINE 3",CIPANT HAS MILD HYPERTENSION BUT NOT ON MEDICATION.,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,RELTEST1,"SAE - RELEVANT TESTS/LAB DATA, LINE 1","THE RELEVANTTESTS/LABORATORY DATA ARE NOT CURRENTLY AVAILABLE TO THE SITE, THEY WILL BE",CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,RELTEST2,"SAE - RELEVANT TESTS/LAB DATA, LINE 2",FORWARDED TO THE LEAD NODE AS SOON AS POSSIBLE AS THEY BECOME AVAILABLE.,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SAENDC01,SECONDARY INV AGENT END DATE,2001,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SAEXDT01,SECONDARY INV AGENT EXP DATE,2002,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SAFREQ01,SECONDARY INV AGENT FREQUENCY,ONCE DAILY,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SAIVSD01,SECONDARY INV AGENT INVEST. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SAKNWN01,IS SECONDARY INV AGENT KNOWN?,YES,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SALOT01,SECONDARY INV AGENT LOT NUMBER,00620052,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SANAME01,SECONDARY INVESTIGATIONAL AGENT NAME,BUP/NX,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SAQUNT01,SECONDARY INV AGENT QUANTITY,1,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SAROUT01,SECONDARY INV AGENT ROUTE,SUBLINGUAL,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SASGDT01,SECONDARY INV AGENT PHYSIC. SIGNED,2002,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SASTDC01,SECONDARY INV AGENT START DATE,2001,CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SAUNIT01,SECONDARY INV AGENT UNIT,"OTHER, SPECIFY",CRF
NIDA-CTN-0002,AE,02_095665,AESEQ,518,SAUNTO01,"SECONDARY INV AGENT UNIT - OTHER, SPECIF",STUDY KIT,CRF
NIDA-CTN-0002,AE,02_097175,AESEQ,675,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097175,AESEQ,676,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,181,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,182,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,183,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,184,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,185,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,186,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,187,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,188,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,189,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,190,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,191,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,192,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,193,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,194,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,195,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,196,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,197,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,198,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,199,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,200,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,201,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,202,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,203,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,204,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,205,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,206,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097455,AESEQ,207,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097852,AESEQ,752,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_097852,AESEQ,753,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_097852,AESEQ,754,RPTTYP,TYPE OF REPORT,ANTICIPATED,CRF
NIDA-CTN-0002,AE,02_097852,AESEQ,755,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,535,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,536,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,537,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,538,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,539,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,540,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,541,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,542,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,543,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098074,AESEQ,544,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098425,AESEQ,656,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098425,AESEQ,657,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_098425,AESEQ,658,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_098425,AESEQ,659,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098425,AESEQ,660,RPTTYP,TYPE OF REPORT,UNANTICIPATED,CRF
NIDA-CTN-0002,AE,02_098425,AESEQ,661,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_098425,AESEQ,662,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_098425,AESEQ,663,RPTTYP,TYPE OF REPORT,INTERCURRENT ILLNESS,CRF
NIDA-CTN-0002,AE,02_099368,AESEQ,732,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099368,AESEQ,733,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099368,AESEQ,734,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099368,AESEQ,735,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099368,AESEQ,736,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099368,AESEQ,737,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099926,AESEQ,545,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099926,AESEQ,546,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099926,AESEQ,547,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099926,AESEQ,548,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099926,AESEQ,549,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
NIDA-CTN-0002,AE,02_099926,AESEQ,550,RPTTYP,TYPE OF REPORT,WITHDRAWAL,CRF
